(redirected from Anastrazole)
Also found in: Dictionary.
Related to Anastrazole: tamoxifen


an aromatase inhibitor used for treatment of advanced breast carcinoma in postmenopausal women; it inhibits conversion of circulating androgens into estrogens.



Pharmacologic class: Nonsteroidal aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D


Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth


Tablets: 1 mg

Indications and dosages

Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer

Adults: 1 mg P.O. daily


• Hypersensitivity to drug or its components
• Women of childbearing age


Use cautiously in:
• ischemic heart disease
• breastfeeding patients
• children (safety and efficacy not established).


• Verify that patient isn't pregnant before giving drug.

Adverse reactions

CNS: headache, weakness, dizziness, depression, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain

Musculoskeletal: decreased bone mineral density, fractures, bone or back pain, muscle weakness

Respiratory: dyspnea, cough

Skin: rash

Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare hypersensitivity reactions (including anaphylaxis, angioedema, urticaria)


Drug-diagnostic tests.Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring

Monitor patient closely for hypersensitivity reactions.
• Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.
• Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).
• Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.
• Monitor liver function test results.

Patient teaching

Instruct patient to immediately notify prescriber if signs and symptoms of hypersensitivity occur (such as itching or swelling of face, lips, or throat).

Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.
• Emphasize importance of preventing pregnancy during therapy.
• Tell patient to contact prescriber if she develops signs or symptoms of depression.
• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that she'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


/anas·tro·zole/ (ah-nas´trah-zōl″) an antineoplastic used for treatment of advanced breast carcinoma in postmenopausal women.


a nonsteroidal aromatase inhibitor.
indication It is prescribed in the treatment of advanced breast cancer for postmenopausal women whose disease has not responded to treatment with tamoxifen.
contraindication The drug is usually effective only in patients with estrogen-dependent tumors.
adverse effects The side effects most often reported include diarrhea, fatigue, nausea, headache, hot flashes, and back pain.


An aromatase inhibitor, which converts androstenedione to estradiol in peripheral fat.
Postmenopausal women with advanced oestrogen-dependent breast cancer that does not respond to tamoxifen; unlike tamoxifen, anastrozole is not associated with increased risk of endometrial cancer.


An anti-oestrogen drug. Anastrozole is an aromatase-inhibitor anti-estrogen drug used in the treatment of advanced breast cancer in post-menopausal women. An aromatase is an enzyme that promotes the conversion of testosterone to the aromatic compound oestradiol (estradiol). This process occurs in women, and its inhibition can reduce oestrogen levels which can be helpful in the control of oestrogen-dependent tumours. The side effects may include any of those due to oestrogen deficiency. A brand name is Arimidex.
References in periodicals archive ?
1) presented data from a pilot study evaluating the effect of anastrazole (Arimidex) on the contralateral (healthy) breast in patients with unilateral breast cancer.
Serum estradiol was lower with anastrazole, and the investigators proposed that the smaller number of follicles in those patients suggests the aromatase inhibitor could produce fewer multiple births.
The trial involved 9,366 patients with invasive, operable breast cancer who had completed primary therapy and who were randomized to receive anastrazole (3,125 patients), tamoxifen (3,116 patients), or a combination of the two (3,125 patients).
The trial involved 9,366 patients with invasive, operable breast cancer who had completed primary therapy and were randomized to receive anastrazole alone (3,125 patients), tamoxifen alone (3,116 patients), or a combination of the two (3,125 patients).
Presumably most of the ER+ patients were taking tamoxifen or anastrazole for years after their diagnosis.
A recent study published in the New England Journal of Medicine showed that a combination of anastrazole (Arimidex[R]) and fulvestrant (Faslodex[R]) improved the overall survival and progression-free survival in women with certain hormone-receptor positive metastatic breast cancers.
This was managed using palliative radiotherapy to control the symptoms and her adjuvant hormonal therapy was switched to Anastrazole (AstraZeneca plc, London, United Kingdom).
The combination of Apoptone and docetaxel destroyed existing tumor cells better than either anastrazole (Arimidex(R)) or tamoxifen, the most common therapies used to treat breast cancer.
Likewise, women treated with anastrazole were less likely to develop contralateral breast cancer; the rates were 1 %, compared with 1.
John Forbes presented the 100-month follow-up from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial comparing 5 years of tamoxifen with 5 years of anastrazole in postmenopausal women with ER-positive breast cancer (University of Newcastle, NWS, Australia; Abstr.
Examples of aromatase inhibitors are anastrazole, exemestane, letrozole.
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.